Anti-SLC19A1 antibody

• Supplier: Abcam
• Catalog: ab62302
• Prices: $380.00
• Sizes: 100 µl
• Host: Rabbit
• Clonality: Polyclonal
• Isotype: IgG
• Applications: ELISA WB IHC-P ICC/IF ICC/IF
• Species Reactivities: Human, Rat
• Antigen: A 14-22 amino acid region within synthetic peptide: MVPSSPAVEK QVPVEPGPDP ELRSWRHLVC YLCFYGFMAQ IRPGESFITP, corresponding to N terminal amino acids 1-50 of Human SLC19A1 Run BLAST with Run BLAST with
• Description: Rabbit Polyclonal
• Gene: SLC19A1
• Conjugate: Unconjugated

Product images

SLC19A1 antibody (ab62302) at 5.0µg/ml (in 5% skim milk / PBS buffer) + Jurkat cell lysate at 10 µgSecondaryHRP conjugated anti-Rabbit IgG at 1/50000 dilution

ICC/IF image of ab62302 stained MCF7 cells. The cells were 4% PFA fixed (10mins) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab62302, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899 Dylight 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling SLC19A1 with ab62302 at 4-8µg/ml. Arrows indicate positively stained epithelial cells of the renal tubule. Magnification: 400X.

Product References

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and - Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and

Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Issa JP, Wistuba II, Kurzrock R. Clin Epigenetics. 2014 Jan 9;6(1):2.

The antiepileptic drugs phenobarbital and carbamazepine reduce transport of - The antiepileptic drugs phenobarbital and carbamazepine reduce transport of

Halwachs S, Lakoma C, Schafer I, Seibel P, Honscha W. Mol Pharmacol. 2011 Oct;80(4):621-9.

Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro - Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro

Marchi E, Paoluzzi L, Scotto L, Seshan VE, Zain JM, Zinzani PL, O'Connor OA. Clin Cancer Res. 2010 Jul 15;16(14):3648-58.